Edward Tenthoff

Kristen Kluska

Leland Gershell

Aydin Huseynov

Catherine Novack

Joseph Pantginis

Boobalan Pachaiyappan

Bubalan Pachayapan

Chris Lemos

Ivan Hosinov

Madison El-Saadi

Madison Wynne El-Saadi

Matthew Venezia

- A class action securities lawsuit has been filed against **Capricor Therapeutics, Inc.** (CAPR) for alleged securities fraud between **October 9, 2024, and July 10, 2025**.  **[1133869_3756bf1ec20640d08242806d5b3ec9bd_0]** 
- The lawsuit alleges that Capricor made false and misleading statements regarding its lead cell therapy candidate, deramiocel, and its ability to obtain a Biologics License Application (BLA) from the FDA, while concealing adverse safety and efficacy data from its Phase 2 HOPE-2 trial.  **[1133869_3756bf1ec20640d08242806d5b3ec9bd_0]** 
- This lawsuit follows Capricor's announcement on **July 11, 2025**, that it received a **Complete Response Letter (CRL)** from the FDA denying the BLA for deramiocel, citing a lack of substantial evidence of effectiveness and the need for additional clinical data.  **[1133869_3756bf1ec20640d08242806d5b3ec9bd_0]** 
- Following this news, Capricor's stock price declined from **$11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025**.  **[1133869_3756bf1ec20640d08242806d5b3ec9bd_0]** 
- Investors have until **September 15, 2025**, to request to be appointed as lead plaintiff in the lawsuit.  **[1133869_3756bf1ec20640d08242806d5b3ec9bd_0]**

Capricor Therapeutics Faces Class Action Lawsuit

CAPRICOR THERAPEUTICS (CAPR)